E. coli strain E1392-75-2A
PreclinicalBiologic
E. coli strain E1392-75-2A is one of 13 biologic programs targeting Resistance. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Resistance
#DrugCompanyPhaseTrials
1Herceptin
RochePhase 2
Keytruda
Merck & Co.Phase 2
Alecensa
RochePhase 2
Alli
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 2
MPDL3280A
CClovis Oncology, Inc.
Phase 2
Third-Generation EGFR-TKI
HHunan Province Tumor Hospital
Phase 2
Propecia
OOrganon and Co
Preclinical
XBD173
NovartisPreclinical
Non-Steroidal Anti-Inflammatory Drug
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Enterotoxigenic Escherichia Coli Infection1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for E. coli strain E1392-75-2A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- NNIZO Food Research